LOS ANGELES, May 7, 2026 /PRNewswire/ — TCL CSOT, a global leader in advanced display technologies and a subsidiary of TCL Technology, is introducing its APEX Pixel framework at SID Display Week 2026. Rooted in the APEX philosophy — which transcends specifications to embody premium experiences that resonate with people — APEX Pixel represents a unified path for pixel-level innovation across FMM OLED, Inkjet-printed (IJP OLED), and LCD, underscoring TCL CSOT’s leadership in frontier display technologies and its commitment to continuous innovation.

“Pixel innovation is the cornerstone of display technology. APEX Pixel is driving coordinated breakthroughs across LCD, OLED, and beyond, infusing every pixel with comfort, eye health, sustainability, and a vision for the future,” said Xiaolin Yan, CTO of TCL Technology, CTO of TCL CSOT. “It also continues to push the boundaries of next-generation technologies such as Micro LED, while enabling extraordinary experiences for the AI era through XR displays.”

FMM OLED: Super Pixel Breakthroughs 

TCL CSOT is redefining next-generation FMM OLED performance with Super Pixel technology, which delivers a powerful trifecta of benefits:

• Higher Clarity: Achieves sharpness comparable to WQHD SPR. By increasing the sub-pixel quantity by approximately 1.8%, it renders images that are more accurate, clear, and finely detailed.
• Smarter Power Use: Optimized data processing reduces power consumption by up to 25% while maintaining exceptional image quality.
• Rapid Refresh: Leverages a Real RGB pixel layout that requires less bandwidth than SPR, enabling refresh rates up to 40% higher for smoother motion.

TCL CSOT is showcasing a suite of groundbreaking Super Pixel mobile displays, each designed to push the boundaries of clarity, efficiency, and refresh performance. 

• World’s First Super Pixel High-Clarity Mobile Display (6.9″): This display delivers an ultra-high 2608×1200 resolution and 420PPI on a 6.9-inch screen, producing razor-sharp text and finely detailed textures. Its ultra-narrow bezels (0.5mm top, 0.8mm sides) create a stunningly immersive, edge-to-edge viewing experience.
• World’s Lowest-Power Consumption Super Pixel Mobile Display (6.9″): Setting a new benchmark in energy efficiency, this 420PPI display combines Super Pixel density with an 8T LTPO ultra-low-power architecture. It reduces IC power consumption by 10% and SoC power consumption by 25% compared to conventional solutions, extending battery life without compromising its 2000 nit peak brightness.
• World’s First Super Pixel High Refresh Rate Mobile Display (6.9″): Designed for next-generation gaming, this display features an ultra-fast 165 Hz refresh rate, improving motion smoothness by 40% over 120 Hz panels for tear-free visuals. Its 7T LTPS architecture intelligently adapts between 60–165 Hz to balance performance and power efficiency.

 IJP OLED: Superior Quality with Greater Flexibility 

Building on TCL CSOT’s decade-long leadership in IJP OLED and its construction of the world’s first 8.6-generation IJP OLED production line (t8), the company is showcasing how IJP OLED technology is transforming the industry with significant advantages in manufacturing and performance. TCL CSOT’s pixel innovation in this area delivers:

• Process Advantages: Reduces reliance on complex vacuum procedures and flexibly adapts to different panel sizes through scalable printhead configurations.
• Image Quality: Real Stripe RGB pixel arrangement ensures exceptional clarity and true-to-life color accuracy.
• Power Optimization: By creating larger light-emitting areas (50%–60% of the pixel), the technology improves luminous efficiency and lowers overall power consumption.

TCL CSOT is showcasing this innovation through the World’s First Foldable & Portable IJP OLED Monitor Display (28″). Featuring a revolutionary tri-fold design, it transforms a compact 16-inch device into an expansive 28-inch ultra-wide screen, demonstrating IJP OLED’s unique capability to enable flexible, high-performance designs that expand the boundaries of display applications.

LCD Innovation: Advancing with RGBC Four-Color Technology 

TCL CSOT is advancing LCD technology for the large-screen domain by incorporating an innovative four-color (RGBC) pixel array.

• Expanded Color Gamut & Accuracy: By adding a fourth (Cyan) sub-pixel to the traditional RGB system, the display can directly generate more saturated and realistic colors, significantly expand the color gamut and enhance color accuracy, especially in cyan tones.
• Enhanced Resolution: The four-color system increases the sub-pixel count and utilizes optimized rendering algorithms to markedly improve resolution, delivering superior performance, especially when rendering high-frequency image details.

This innovation is demonstrated in the World’s Highest Image Quality WHVA Ultra LCD TV Display (85″), featuring a native RGBC four‑color pixel array that achieves 131% of the BT.2020 color gamut. Delivering true four‑color performance at the hardware level, it sets a new benchmark for LCD innovation with exceptionally vivid, natural, and clear images.

By continuously evolving its technology portfolio to meet diverse scenarios, TCL CSOT demonstrates its commitment to setting new standards in display innovation and ensuring that advanced display solutions enrich everyday life for users worldwide.

– End –

About TCL CSOT

Established in 2009, TCL China Star Optoelectronics Technology Co., Ltd. (TCL CSOT) is a leading global innovator in display technologies. Its LCD, OLED, and MLED solutions power applications across TVs, smartphones, tablets, laptops, monitors, automotive systems, VR/XR, and commercial displays. With a clear strategic direction set by its advanced display technology brand APEX, TCL CSOT invests continuously and strategically in R&D, driven by a mission to amaze, protect and inspire all people through endlessly innovative display technology. As part of TCL’s Worldwide Olympic Partnership, TCL CSOT is proud to deliver display solutions that elevate experiences on the global stage.

SUZHOU, China, May 7, 2026 /PRNewswire/ — Recently, BrightGene Bio-Medical Technology Co., Ltd. (hereinafter referred to as “BrightGene Bio-Medical ” or “the Company”) announced that its proprietary GLP-1 (glucagon-like peptide-1)/GIP (glucose-dependent insulinotropic polypeptide) dual receptor agonist, BGM0504 injection, has achieved positive topline results from a Phase III clinical trial (CTR20243983/NCT06704581) evaluating its efficacy and safety in participants with overweight or obesity.

Against the backdrop of intensifying global competition in weight management therapeutics and clinical efficacy approaching a plateau, industry focus is gradually shifting from the singular metric of “magnitude of weight loss” toward comprehensive cardiometabolic benefits and population coverage capabilities that offer greater clinical value and real-world translational impact. Consequently, the evaluation framework for weight management drugs is undergoing a fundamental transformation.

Phase III data for BGM0504 demonstrated that while achieving a mean significant weight reduction of 19.3% and a waist circumference decrease of 16.5 cm, the hypertensive population experienced mean reductions in systolic and diastolic blood pressure of 22.9 mmHg and 12.9 mmHg, respectively, from baseline after 36 weeks of treatment. After 52 weeks of treatment, participants achieved a mean uric acid reduction of 70.7 μmol/L, with total body bone mineral density/lumbar spine bone mineral density/hip bone mineral density increasing by 0.3%, 1.4%, and 3.9%, respectively. Blood lipids, blood glucose, and other cardiometabolic parameters also demonstrated outstanding comprehensive improvement capabilities. Furthermore, while achieving robust efficacy, BGM0504 injection demonstrated exceptional overall tolerability, with the high-dose group showing a discontinuation rate of only 0.7%.

Against the backdrop of simultaneous improvements in weight reduction, waist circumference, blood pressure, uric acid, bone mineral density, and multiple metabolic parameters, BGM0504 has evolved beyond the attributes of a singular weight management tool to embody comprehensive cardiometabolic regulation capabilities oriented toward long-term chronic disease management.

19.3% Weight Reduction and 16.5 cm Waist Circumference Decrease: Exceptional Weight and Fat Loss Capabilities Demonstrated Simultaneously

As weight reduction enters a plateau phase, competition is shifting toward overall capabilities, with weight loss magnitude alone no longer sufficient to create significant differentiation. BGM0504 achieved a 19.3% weight reduction over a 52-week treatment period, positioning it at the upper end of the topline range for global dual-target mechanisms.

Cross-dose comparisons reveal that BGM0504 demonstrates significant leadership over competing products at the low-dose level, maintains its advantage at the mid-dose level, and reaches the upper limit of the industry range at the high-dose level. BGM0504 exhibits a clear efficacy signal at the low dose (5 mg), with further enhancement at higher doses while maintaining relatively stable tolerability. This characteristic of “low-dose efficacy with dose-dependent enhancement” represents a meaningful point of differentiation among current competing products. In contrast, some competing products rely more heavily on mid-to-high doses to demonstrate efficacy, with relatively limited performance and disclosure at low-dose levels.

This characteristic holds multiple implications for clinical practice. On one hand, the ability to produce substantial weight reduction at low doses helps build patient confidence early in treatment and reduces reliance on rapid dose escalation, thereby achieving a better balance between efficacy and tolerability. On the other hand, it enables potential application to a broader patient population. For example, in individuals who have not yet reached severe obesity criteria but have developed metabolic abnormalities or weight-related risks, low-dose intervention may serve as a more gentle initial therapeutic approach.

Evaluating a weight management drug requires looking beyond weight reduction data to assess comprehensive outcomes, particularly changes in body shape. Waist circumference reduction reflects visceral fat loss and body shape transformation, addressing the core needs of most individuals seeking weight loss. Beyond body weight, waist circumference—a key indicator of visceral fat—also demonstrated superior results, with participants in the 15 mg dose group achieving a reduction of 16.5 cm, significantly outperforming competing products.

This result indicates that its efficacy has extended from “weight change” to “risk profile improvement.” Consequently, BGM0504 not only ranks in the top tier for magnitude of weight reduction, but also demonstrates advantages of earlier onset, greater waist circumference reduction, and more superior efficacy in fat distribution, a dimension that is closer to the essence of the disease.

In the dimension of “who can help more people lose weight,” BGM0504’s advantage is even more pronounced. The proportion of participants achieving ≥5% weight loss from baseline reached 84.7%, 89.8%, and 94.6% in the 5 mg, 10 mg, and 15 mg dose groups, respectively.

In the more clinically meaningful deep weight loss ranges (≥15%, ≥20%), this advantage is further amplified. In the 15 mg group, 67.3% of participants achieved ≥15% weight loss, and 48.9% achieved ≥20% weight loss—nearly half of patients achieving deep weight loss, approaching the intervention range of bariatric surgery. This indicates that its clinical value is extending from “weight management” to “metabolic state remodeling.”

Overall, BGM0504’s core competitive advantage has shifted from “how much weight is lost” to “how much waist circumference is reduced,” and ultimately to “enabling more people to achieve stable weight loss and enter the deep weight loss range.” As the industry transitions from “single-point magnitude competition” to “population-level efficacy and real-world translation,” the comprehensive advantages demonstrated by BGM0504 are emerging as the new competitive differentiator.

SBP/DBP Reductions of 22.9/12.9 mmHg with 92.9% Target Achievement Rate, Demonstrating Antihypertensive Intervention Potential

Beyond weight reduction and waist circumference, blood pressure changes represent another noteworthy dimension in this dataset. Lilly’s tirzepatide and Novo Nordisk’s semaglutide did not fully investigate this population in their Phase III trials. The enrollment design itself reflects a higher level of clinical ambition. On one hand, over 60% of individuals with obesity have comorbid hypertension; the study’s inclusion of patients with comorbid hypertension makes the results more aligned with the common real-world clinical scenario of “obesity + hypertension.” On the other hand, the disclosure not only reports the magnitude of blood pressure reduction but also presents the blood pressure target achievement rate, elevating blood pressure from merely a “concomitant improvement” to a parameter with complete evaluative information.

In the population with comorbid hypertension and uncontrolled blood pressure, mean systolic blood pressure decreased by 22.9 mmHg and diastolic blood pressure by 12.9 mmHg, with 92.9% of patients achieving target blood pressure. In contrast, previous studies of similar drugs have predominantly presented blood pressure outcomes as trend changes, with relatively limited systematic disclosure of target achievement rates. Therefore, these results provide a complementary perspective in terms of data completeness.

In clinical practice, monotherapy with a single antihypertensive agent (ACEI [angiotensin-converting enzyme inhibitor, such as captopril]/ARB [angiotensin II receptor blocker, such as valsartan]/CCB [dihydropyridine calcium channel blocker, such as nifedipine]/diuretic [such as hydrochlorothiazide]) typically achieves only approximately 8–12 mmHg reduction in systolic blood pressure. Reductions exceeding 20 mmHg often require multi-mechanism combination therapy. It is important to note that this change was observed in the more challenging population of individuals with obesity and comorbid hypertension, who typically present with insulin resistance and multiple metabolic abnormalities, making blood pressure control relatively more difficult. Therefore, the simultaneous observation of improvements in both body weight and blood pressure in this population holds meaningful clinical reference value.

From a broader chronic disease management perspective, hypertension and diabetes are highly comorbid in clinical practice and jointly contribute to the development and progression of cardiovascular and cerebrovascular events. According to guideline stratification, hypertensive patients with comorbid diabetes are often directly classified into higher risk categories, requiring more stringent blood pressure control targets and more urgent intervention. In this context, if metabolic intervention can simultaneously impact body weight, blood pressure, and glycemic parameters, it may produce synergistic effects on multiple metabolic abnormalities at early stages of risk. This characteristic makes the application value of these data in the continuum of “obesity—hypertension—glycometabolic abnormalities” worthy of further attention.

Additionally, its safety profile is equally noteworthy. Despite the substantial magnitude of blood pressure reduction, no hypotensive events were observed during the study, suggesting that the blood pressure changes occurred in a generally stable manner. From a mechanistic perspective, this result more closely resembles comprehensive changes driven by metabolic improvement rather than a singular antihypertensive pathway.

Therefore, against the backdrop of synergistic changes in weight reduction, blood pressure, and multiple metabolic parameters, BGM0504 demonstrates not only improvement in individual indicators but also coordinated effects across multiple metabolic risk factors. This characteristic provides a new observational dimension for its potential application in metabolism-related risk management.

Uric Acid Reduction of 70.7 μmol/L, Demonstrating Potential Gout Benefit Capability

Beyond blood pressure, other metabolic parameters such as uric acid also demonstrated consistent improvement trends.

Uric acid, a metabolic parameter closely associated with gout, also demonstrated clinically meaningful improvement signals. Data showed that BGM0504 treatment resulted in a mean uric acid reduction of approximately 70.7 μmol/L, a magnitude that has entered the intervention range of clinical therapeutics. In the treatment of hyperuricemia, conventional urate-lowering therapies (such as the xanthine oxidase inhibitor febuxostat and the uricosuric agent benzbromarone) typically achieve reductions of approximately 60–120 μmol/L.

Note: Uric acid-lowering drugs are indicated for the treatment of hyperuricemia and gout. BGM0504 acts via a metabolic intervention pathway with different indications. The data are for magnitude reference only and do not constitute a therapeutic efficacy comparison.

Generally, a reduction of approximately 60 μmol/L in uric acid can significantly decrease the risk of gout attacks. Therefore, this result indicates that its effect extends beyond metabolic parameter improvement and may translate into intervention potential for gout risk.

Furthermore, compared to tirzepatide (SURMOUNT-1 study), BGM0504 demonstrated stronger and more balanced improvement trends across multiple core lipid parameters.

For triglycerides, BGM0504 achieved a reduction of approximately 33.6%, significantly superior to tirzepatide’s 24.8%, with a gap of nearly 9 percentage points. This has entered the 20%–50% range of action typical of traditional lipid-lowering agents, demonstrating an intervention intensity comparable to standard lipid-lowering agents. Additionally, low-density lipoprotein cholesterol decreased by approximately 12.7%, superior to tirzepatide’s 5.8% reduction, while total cholesterol decreased by approximately 7.4%, exceeding tirzepatide’s 4.8%. Based on rough calculations of the LDL-C/HDL-C ratio, this atherosclerosis-related ratio decreased by approximately 18.6% following BGM0504 treatment, suggesting that it does not merely lower a single lipid parameter, but rather reduces “bad cholesterol” while elevating “good cholesterol,” thereby driving overall improvement in lipid risk profile.

As an important extension of the metabolic system, bone metabolism is highly coupled with glucose and lipid metabolism as well as energy balance. At the bone metabolism level, after 52 weeks of treatment, participants across all dose groups (pooled 5 mg/10 mg/15 mg) achieved relative increases from baseline of 0.3% in total body bone mineral density (BMD), 1.4% in lumbar spine BMD, and 3.9% in hip BMD. In previous studies, weight loss is often accompanied by changes in bone mineral density. Relevant phenomena have also been observed for certain GLP‑1 receptor agonists such as semaglutide across multiple trials, and such changes are generally attributed to reduced skeletal loading following body weight reduction. Notably, in the Phase III clinical program of BGM0504, significant weight loss was accompanied by no declining trend in BMD; instead, consistent increases in bone mineral density were achieved.

Body weight, blood pressure, uric acid, blood lipids, blood glucose and bone mineral density are no longer discrete endpoint indicators, but integrated into a continuous metabolic regulatory cascade. Mechanistically, BGM0504 does not merely regulate a single individual parameter; rather, it drives holistic remodeling of the metabolic system.

Discontinuation Rate as Low as 0.7%, Corresponding to Higher Patient Retention and Long-Term Adherence

In the context of outstanding efficacy performance, safety becomes one of the critical factors in product evaluation. Across different dose levels of BGM0504, treatment discontinuation due to adverse events (AEs) can more directly reflect the drug’s sustainable use capability in real-world settings.

At the high-dose level, BGM0504 maintained a discontinuation rate of approximately 0.7%, which not only did not increase with dose escalation but remained at a lower level, significantly below competing products by several-fold.

Unlike most products where discontinuation rates increase with dose escalation, BGM0504 actually demonstrated further reduction at the high-dose level, exhibiting the rare characteristic of “dose-independent discontinuation.”

Further dissection of the data structure reveals that the differentiation is reflected not only in magnitude but also in result consistency. In the full analysis set (FAS) and per-protocol set (PPS), the 15 mg group achieved weight reductions of 19.2% and 19.3%, respectively, while the 5 mg and 10 mg groups also demonstrated comparable results of 14.3%/14.6% and 17.3%/16.9%, respectively. This indicates that weight reduction effects are more evenly distributed across the study population, with the majority of patients achieving clear improvement.

A discontinuation rate of approximately 0.7%, combined with comparable results between the full analysis set (FAS) and per-protocol set (PPS), suggests that efficacy can be demonstrated relatively consistently across different populations and implementation conditions. This characteristic reflects, on one hand, favorable overall tolerability that helps maintain treatment continuity; on the other hand, it indicates relatively even distribution of efficacy, with results not dependent on a small subset of high-responder individuals. Its value is no longer reflected solely in magnitude of efficacy, but also in how many patients can sustain use and achieve stable outcomes.

From an overall data structure perspective, the value demonstrated by BGM0504 is no longer confined to singular weight reduction magnitude. The approximately 19.3% weight reduction positions it at the current mainstream upper limit for GLP-1 class medications, while in the dimensions of population coverage and deep weight loss, it further embodies the characteristic of “enabling more patients to achieve stable weight reduction outcomes.” Concurrently, the blood pressure changes observed in the population with comorbid hypertension place its antihypertensive magnitude within the range of common clinical therapeutic interventions. Further layered with simultaneous improvements in multiple parameters including blood lipids and uric acid, its action has extended from singular weight management to synergistic changes across multidimensional metabolic parameters.

The term cardiometabolic generally refers to a cluster of interrelated risk factors including body weight, blood pressure, blood lipids and blood glucose. Clinically, these factors rarely exist in isolation; instead, they collectively contribute to the onset and progression of cardiovascular and cerebrovascular diseases.

Cardiometabolic diseases (CMDs) represent an umbrella term for this interconnected spectrum of disorders. They encompass metabolic conditions such as obesity, type 2 diabetes and dyslipidemia, as well as cardiovascular complications including hypertension, ischemic heart disease (IHD), heart failure (HF), and peripheral vascular diseases. Recognized as the leading cause of death worldwide, CMDs are fundamentally driven by cardiovascular damage resulting from metabolic abnormalities.

Within this framework, the focus of disease management has gradually shifted from single indicator control to the synergistic improvement of multiple metabolic parameters. Against the backdrop that global pharmaceutical companies widely adopt the cardiometabolic framework to define metabolism-related disorders, such clinical data imply more than a simple expansion of indication scope. It embodies an evolving therapeutic paradigm: modulating multiple cardiometabolic risk factors through a single pharmacological mechanism.

In this context, BGM0504 delivers not only enhanced weight loss efficacy, but also distinctive synergistic improvements across multiple cardiometabolic dimensions, including blood pressure, glucose metabolism, lipid metabolism and uric acid levels. This profile suggests its potential value extends beyond standalone weight management to the comprehensive intervention of multiple metabolic risk factors. It offers a promising perspective for the multidimensional clinical management of cardiometabolic diseases.

Guided by its APEX philosophy, TCL CSOT extends its vision through APEX Pixel, delivering immersive, efficient, and eye‑friendly display experiences across home entertainment, mobile communication, smart mobility, and personal immersion.

LOS ANGELES, May 7, 2026 /PRNewswire/ — TCL CSOT, a global leader in advanced display technologies and a subsidiary of TCL Technology, today presented its forward‑looking vision for the display industry at SID Display Week 2026. Anchored in its APEX philosophy, this vision is expressed through the APEX Pixel framework, which delivers pixel‑level breakthroughs across FMM OLED, IJP OLED, LCD, and other advanced display technologies. At the event, TCL CSOT showcases how these innovations are shaping the next generation of experiences in home entertainment, smart mobility, mobile communication, and immersive experience.

“APEX is more than a benchmark in display technology. It is a bridge connecting us with consumers worldwide,” said Jun Zhao, SVP of TCL Technology and CEO of TCL CSOT. “Through APEX-led, full-stack innovation, TCL CSOT is making ‘Display the Future’ accessible in the era of Al across every aspect of everyday life. This year, our IJP OLED solutions will also debut in the mid-size segment.”

The APEX Philosophy: A Human‑Centric Vision for Displays

APEX is TCL CSOT’s systematic answer to what defines a truly great display. It is built on four pillars that guide research and development to ensure every innovation delivers meaningful, human-centric benefits:

• Amazing Display Experience – Elevating immersion, fluidity, and vivid color performance across scenarios, from mobile screens to the large-format displays.
• Protective of Eye Health – Integrating natural light technologies and visual science to balance stunning picture quality with long‑term visual comfort.
• Eco‑Friendly to Build and Use – Embedding eco‑friendly principles into development, with low‑power OLED and energy‑efficient LCD solutions that reduce consumption while maintaining premium performance.
• X‑Unlimited Imaginative Potential – Exploring future possibilities with AI-driven holographic displays, Micro LED, and XR applications that expand the boundaries of interaction and creativity.

Bringing the APEX Vision to Life Across Everyday Scenarios

At SID Display Week 2026, TCL CSOT demonstrated how its APEX philosophy — embodied in the APEX Pixel framework — is applied to enhance key aspects of modern life.

Home Entertainment Scenario

Bringing the “Amazing Display Experience” pillar to the living room, the World’s Largest HVA Ultra TV Display (130″) breaks traditional LCD size boundaries and redefines large-format design with an ultra-slim 29.8 mm profile. Meanwhile, the World’s Highest Image Quality WHVA Ultra LCD TV Display (85″) uses a native RGBC four-color pixel arrangement. This APEX-driven innovation delivers color reproduction that is more lifelike and natural, creating a deeply immersive home cinema experience for the whole family.

Smart Mobility Scenario

The APEX vision for a seamless, integrated user experience extends into the vehicle with the Intelligent Cockpit Display Suite 3.0. Its centerpieces — the World’s First IJP OLED Sliding Central Control Display (28″), a dynamic sliding control screen, and the World’s First IJP OLED Curved Armrest Display (28″), a sculpted curved armrest screen — showcase how the flexibility of IJP OLED technology can create a more intuitive, integrated, and seamless “third living space.”

Daily and Business Scenario

To meet the evolving demands of modern mobile communication, TCL CSOT’s APEX-driven solutions prioritize performance and flexibility, with Super Pixel technology delivering mobile displays with Higher Clarity, Smarter Power Use, and Rapid Refresh.

For hybrid work, the World’s First Foldable & Portable IJP OLED Monitor Display (28″) brings IJP OLED technology into a highly versatile design, transforming from a compact device into an expansive ultra-wide screen that empowers productivity anywhere.

Immersive Entertainment Scenario

Pushing the boundaries of imagination, TCL CSOT’s “X-Unlimited Imaginative Potential” vision for XR is realized in forward-looking concepts. Innovations like the World’s Highest PPI Single-Chip Full-Color Si-Micro LED Display (0.28″) and the World’s Highest 1700PPI Real RGB G-OLED Display (2.24″) offer a glimpse into a future of deeply personal and interactive entertainment, made possible by the pioneering spirit of APEX.

– End –

About TCL CSOT

Established in 2009, TCL China Star Optoelectronics Technology Co., Ltd. (TCL CSOT) is a leading global innovator in display technologies. Its LCD, OLED, and MLED solutions power applications across TVs, smartphones, tablets, laptops, monitors, automotive systems, VR/XR, and commercial displays. With a clear strategic direction set by its advanced display technology brand APEX, TCL CSOT invests continuously and strategically in R&D, driven by a mission to amaze, protect and inspire all people through endlessly innovative display technology. As part of TCL’s Worldwide Olympic Partnership, TCL CSOT is proud to deliver display solutions that elevate experiences on the global stage.

BEIJING, May 6, 2026 /PRNewswire/ — China Petroleum & Chemical Corporation  (“Sinopec”, HKG: 0386) has unveiled the “Fenghuo” industrial AI agent, the first digital expert in the petrochemical sector capable of actively participating in production operations.

The “Fenghuo” AI agent can analyze production data, interact with industrial software, and generate scientific research and engineering outcomes, essentially functioning as a “digital colleague” for petrochemical employees. The innovation marks the first time that AI achieving independent operational capability in the petrochemical sector, a key milestone in Sinopec’s efforts to advance AI from a general-purpose tool to a core driver of industrial productivity—infusing new technological momentum into the high-quality development of the entire industry chain.

Built on Sinopec’s “Great Wall” large model, the “Fenghuo” intelligent agent achieves three major breakthroughs:

• Deep domain knowledge accumulation: integrating over one billion expert insights and experiences, the equivalent of carrying an entire petrochemical library with every task while being capable of continuous learning and autonomous iteration.
• Precise utilization of specialized toolchains and enterprise data: operates industrial simulation, process modeling, and other systems to complete engineering calculations.
• Stable execution of complex tasks over extended periods: to autonomously break down multi-step industrial processes and maintain reliable performance during continuous operations that last several hours.

The first deployment of “Fenghuo” AI agent spans four roles: Fenghuo Scientist, Fenghuo Engineer, Fenghuo Programmer, and Fenghuo Assistant. The Scientist and Engineer serve as core productivity roles, autonomously analyzing tasks and leveraging industrial software to conduct specialized work, such as dynamic oilfield development analysis and refining process optimization. Meanwhile, the Fenghuo Assistant helps employees with data organization, report writing, and other routine tasks, improving daily office efficiency.

In recent years, Sinopec has continuously advanced the vision of a “Digital and Intelligent Sinopec.” Moving forward, the company will take the “Fenghuo” industrial AI agent as a springboard to further promote the integrated application and iterative evolution of artificial intelligence across the petrochemical industry chain, continuously injecting new digital intelligence into the high-quality development of China’s energy and chemical sector.

For more information, please visit http://www.sinopec.com/listco/en/.

LOS ANGELES, May 6, 2026 /PRNewswire/ — SID Display Week 2026, regarded as the barometer of the global display industry, opened in Los Angeles, the United States, on May 5, Pacific Time. BOE, a global leader in the display sector, has made its twelfth consecutive appearance at this prestigious event, bringing more than 30 world-first or industry-first innovations powered by its three technology brands. Notably, 65% of the exhibits are industry debuts, setting new records in industrialization maturity and industry leadership of pioneering technologies.

Centered around the three pillars of technology leadership, AI empowerment, and global collaboration, BOE exhibits the full spectrum of display technologies, including LCD, OLED, MLED, and AI-integrated solutions. It demonstrates end-to-end leadership spanning from foundational technological innovation to industrial ecosystem building, embodying its global development path that is “anchored in technological resilience, connected through ecosystem synergy, and driven by shared value creation.” During the event, BOE hosted the first overseas AI+ forum and received multiple awards from the Society for Information Display (SID) for its deep technical expertise and abundant innovations. Liu Zhiqiang, Senior Vice President of BOE, was awarded the Special Contribution Award, highlighting BOE’s standing as a benchmark in high-end display and innovative applications.

Notably, at SID 2026, BOE partnered with Pantone, the global authority on color, to take a significant step toward standardizing color in display technology. BOE’s f-OLED technology brand reached a major milestone as its 14-inch TADF wide-gamut OLED display technology officially received Pantone color accuracy certification “Pantone Validated”, becoming the first in China’s display industry to receive this recognition. This achievement marks a new professional benchmark for BOE in color precision and ushers in a new era of “Color Display Science.”

Breakthrough innovations: diverse world-first technologies set new industry benchmarks

At SID Display Week 2026, BOE redefines what makes a “great display” through forward-looking technology roadmaps and systematic product innovation, setting the pace for the global display industry.

In the LCD exhibition zone, BOE’s 85-inch UB Cell 5.0 RGBX Ultra TV features the original “RGBX panel + RGBX backlight” four-primary-color fusion display technology. It covers 130% of the BT.2020 color gamut, setting a new benchmark for high-end large-size displays. In terms of f-OLED, BOE has achieved breakthroughs in OLED display clarity and “crease-free” OLED display technology. As the first in the industry to define display clarity, BOE pioneered the clarity index as a quantitative evaluation model for display clarity. It established a correlation model that bridges subjective human perception with objective data, translating subjective feeling into four core quantifiable factors: color, layering, definition, and HDR performance. Devices equipped with this technology have a clarity index of over 85, delivering crystal-clear visuals. BOE’s mirror-like creaseless foldable OLED display, through innovations in both structure and materials, reduces crease depth and crease slope by 60%, while boosting mechanical strength by 50%. The product tops the industry in terms of crease performance, with virtually no crease perceptible to the touch and visible to the eye. An ultra-low temperature folding test at minus 40 degrees Celsius was conducted on site. The display remained flat after repeated folding in extreme environments, a testament to BOE’s latest breakthrough in flexible OLED technology. In the α-MLED exhibition lineup, BOE debuts the world’s first 205-inch COG ultra-slim HDR Micro LED product. By combining LTPS technology with GIA design and high-flatness glass substrates, it supports seamless splicing with a module thickness of merely 5mm, creating an unprecedented premium ultra-large display experience.

Underlying its ever-evolving technical capabilities are breakthroughs in Oxide and Beneficial Natural Light (BNL) technologies. The 24.5-inch True 1000Hz Native FHD gaming monitor draws wide attention. Harnessing the high electron mobility of Oxide TFTs, it delivers native 1000Hz refresh rates and true 1000Hz FHD. Combined with a 1ms ultra-fast response time and the BOE Low Motion Blur (BLMB) technology, it ensures smooth, fluid visuals even in high-speed motion scenes. On top of ultra-high refresh rates, it still boasts high color gamut coverage and ultra-wide viewing angles, striking the perfect balance between high refresh rates and exceptional picture quality and setting new standards for gaming displays that prioritize both speed and fidelity. The BNL technology stands as a key milestone in BOE’s research and development of eye-friendly display solutions. Through spectral optimization, polarization modulation, beam shaping, and temporal adaptation, it accurately replicates the beneficial properties of natural light. The industry’s first 13.8-inch eye-friendly tablet incorporates seven core BNL technologies, such as the pioneering random depolarization film (RDF) technology, original infrared light technology, and industry-best full-spectrum technology. The product offers a healthy and comfortable viewing experience akin to natural light.

“AI Plus” strategy: Blue Whale Large Model enables scenario-based intelligence

AI is emerging as the key transformative force reshaping the display industry. BOE is advancing the “AI Plus” strategy focused on manufacturing, products, and operations. Leveraging its Blue Whale Large Model, BOE is accelerating the deep integration of AI across the entire display industry chain.

BOE presents the industry-savvy large model for display at the exhibition, along with a range of industry-first or industry-leading AI applications. This model boasts the richest industry data and widest application scenarios, covering the entire display industry chain. Built on high-quality datasets, a high-performance intelligent computing platform, and a comprehensive AI security framework, the model has been implemented in manufacturing, R&D, operations, and other processes, empowering AI-driven innovation and promoting the company’s smart transformation and value realization.

BOE showcases smart office products including the AI Whiteboard and AI Sketch Pad, which empower diversified scenarios such as office work, design, and training. In terms of entertainment scenarios, the world’s first 18-inch 4K 240Hz glasses-free 3D laptop powered by BOE adopts self-developed AI technologies like eye tracking and dynamic interpolation, which greatly enhance the smoothness of 3D content and video playback, delivering an immersive, glasses-free viewing experience. Plus, BOE has integrated AI technology into automotive, home, and other scenarios, advancing human-machine interaction toward multimodal intelligence and offering new ideas for the large-scale application of AI on display products.

Notably, BOE hosted the industry’s first AI+ forum at Display Week 2026 and unveiled a logo symbolizing its foundational AI capabilities. From systematic development of foundational AI capabilities to empowerment via the Blue Whale Foundation Model to best practices in AI Factory, BOE is building a new intelligent ecosystem for the display industry driven by its “AI Plus” strategy. This logo will appear on all AI applications powered by BOE.

Global footprint expansion: open collaboration fosters shared prosperity

BOE has stayed committed to market-based, international, and professional development. More than three decades of development have demonstrated that genuine globalization must be built on the foundation of independent innovation in core technologies. Amid a new round of global industrial chain restructuring, BOE has established a proven and future-oriented globalization framework.

• Geographical reach: BOE has shifted from a single focus on cross-border trade to a phase of deep globalization integrating R&D, manufacturing, marketing, and services. Currently, BOE operates six regional marketing platforms and two overseas manufacturing bases worldwide. Its business spans 20 countries and regions, with nearly 6,000 overseas employees. Overseas revenue accounts for over 50% of the total, and it has more than 5,000 global ecosystem partners. The company is deeply embedded in the higher value-added segments of global value chains.
• Development path: BOE has moved from “product export” to “capability enablement,” establishing a new globalization model anchored on three pillars: technological resilience, ecosystem synergy, and shared value creation. With a portfolio of over 100,000 patents, BOE continuously delivers innovative technologies to global partners. Through a two-way mechanism of going global and bringing in, it empowers the world with China’s display technology and industry experience, while bringing home overseas models and best practices. Additionally, BOE embeds the philosophy of the industry’s first sustainability brand “ONE” (Open Next Earth) into global operations, harmonizing business logic and social value.
• Strategic principles: To ensure steady and continued global expansion, BOE acts on the principles of strategic resolve, customer-centric development, win-win partnerships, and shared social value.

BOE’s globalization strategy is not merely about scale expansion but represents a value leap from “successful practices rooted in China” to “enabling local success worldwide” across the global display landscape.

Scenario-based innovation: partnerships for accelerated innovation and application

During the event, BOE held an exclusive technology marketing event for key partners under the theme “Define the Future—Wonderful Tech, Wonderful Life,” with ever-evolving technologies and products integrated into diverse scenarios including 3D cinema, entertainment, gaming, office, smart mobility, and healthcare. In immersive settings, BOE engaged in in-depth exchanges and collaborative co-creation with partners, embodying its commitment to Tech for Good. BOE also launched the new-gen BLMB technology with ASUS, marking a critical breakthrough of their joint laboratory in high-end laptop display. Since its establishment, the laboratory has been dedicated to collaborative R&D and industrial application of cutting-edge display technology. The launch of the latest BLMB technology signifies a key step in the innovation and commercialization of high-end display technology.

Guided by the “Empower IoT with Display” strategy, BOE will consistently lead the global display industry through technological innovation. By deepening AI integration and pursuing green, sustainable development, it will continue to develop great displays recognized as industry benchmarks and work with global partners to open a new chapter of smart display.